Copper gluconate
CAS 527-09-3
Copper gluconate (CAS 527-09-3) is a pharmaceutical compound with 0 bioactivity targets and 134 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Copper gluconate is linked to DTXSID4035960 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| COPPER GLUCONATE | 2839 | SU | MTHSPL |
| copper gluconate | 2839 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Copper gluconate used for in pharmaceutical contexts?
Copper gluconate (CAS 527-09-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Copper gluconate?
Copper gluconate has 134 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal discomfort, Abdominal distension, Abdominal pain upper, Accidental exposure to product, Alopecia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Copper gluconate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Copper Gluconate with EU status "permitted".
What clinical phase is Copper gluconate in?
No phase 1-4 clinical development badge is rendered for Copper gluconate because the matched compound identifier rows do not contain a max-phase value.